NCT00510133View on ClinicalTrials.gov

A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

August 31, 2014

Conditions
Acute Myelogenous Leukemia
Interventions
BIOLOGICAL

GRNVAC1

Autologous dendritic cell vaccine

Trial Locations (6)

30322

Emory University School of Medicine, Atlanta

43210

Ohio State University, Columbus

60153

Loyola University Medical Center, Maywood

63110

Washington University School of Medicine, Siteman Cancer Center, St Louis

68198

University of Nebraska Medical Center, Omaha

75390

UT Southwestern Medical Center, Dallas

Sponsors
All Listed Sponsors
lead

Asterias Biotherapeutics, Inc.

INDUSTRY

NCT00510133 - A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML) | Biotech Hunter | Biotech Hunter